Ferdinandos Skoulidis, MD, PhD
Approximately 25% to 30% of patients with non–small cell lung cancer (NSCLC) have activating mutations in KRAS
, creating a challenging unmet treatment need, explained Ferdinandos Skoulidis, MD, PhD.
-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.
OncLive: Please provide an overview of your presentation.
I discussed the role of biomarkers in the management of NSCLC. This is a very topical theme because lung adenocarcinoma is emerging as the pinnacle of precision cancer medicine among the solid tumors, with the recognition that NSCLC does not constitute a single disease. NSCLC consists of many different molecularly definitive entities, each of which needs to be treated in a unique way.
... to read the full story